Pancreatic Cancer Research

ResearcherMichael E. DeBakey VA Medical CenterActive in the last 2 years

Mien‐Chie Hung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4317-4740; OpenAlex author ID A5076834432; NIH RePORTER profile ID 1860004. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 6)
Trials
0
Grants
1
Labs led
1
Collaborators
103
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 2 papers, 1 grant

Papers 18

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Last author DOI 10.1038/s41467-026-72271-5↗
  2. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Co-author DOI 10.1038/s41467-026-75132-3↗
  3. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  4. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  5. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Last author DOI 10.1101/2024.10.20.619300↗
  6. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  7. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.1038/s41598-021-04095-w↗
  8. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Co-author DOI 10.1038/s41467-021-27349-7↗
  9. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma ce… Last author PMID 33520371↗
  10. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  11. Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2α in Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001248↗
  12. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2018.02.012↗
  13. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.aat3487↗
  14. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  15. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. Last author PMID 28401019↗
  16. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Last author DOI 10.1158/0008-5472.can-16-0715↗
  17. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-3776↗
  18. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2011.12.006↗

Grants 1

  1. Stem Cell Biology & Cellular Therapy Program P30CA016672↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dihua Yu · 5 shared papers, 1 shared grant, 2021–2026 · strength 1.49
  2. Paul J. Chiao · 8 shared papers, 2012–2026 · strength 0.92
  3. Haoqiang Ying · 8 shared papers, 2017–2026 · strength 0.90
  4. Anirban Maitra · 7 shared papers, 2018–2026 · strength 0.87
  5. Huamin Wang · 9 shared papers, 2012–2026 · strength 0.83
  6. Elizabeth J. Shpall · 1 shared grant, 2026 · strength 0.71
  7. Albert C. Koong · 1 shared grant, 2026 · strength 0.71
  8. Kristy Brock · 1 shared grant, 2026 · strength 0.71
  9. Scott Kopetz · 1 shared grant, 2026 · strength 0.71
  10. Jianhua Ling · 6 shared papers, 2012–2026 · strength 0.65
  11. Jun Yao · 6 shared papers, 2017–2024 · strength 0.63
  12. Yongkun Wei · 5 shared papers, 2016–2026 · strength 0.61
  13. Jie Fu · 4 shared papers, 2017–2026 · strength 0.56
  14. Li‐Yuan Bai · 3 shared papers, 2022–2026 · strength 0.52
  15. Ching-Fei Li · 3 shared papers, 2024–2026 · strength 0.51
  16. Ying‐Nai Wang · 3 shared papers, 2018–2026 · strength 0.42
  17. Jason B. Fleming · 5 shared papers, 2012–2024 · strength 0.36
  18. Liuqing Yang · 2 shared papers, 2021–2023 · strength 0.27
  19. Ya’an Kang · 4 shared papers, 2012–2024 · strength 0.27
  20. Ronald Anthony Depinho · 3 shared papers, 2017–2024 · strength 0.25
  21. Rosa F. Hwang · 3 shared papers, 2016–2024 · strength 0.25
  22. Wenjuan Yin · 2 shared papers, 2021–2024 · strength 0.25
  23. Xuan Zhou · 1 shared paper, 2026 · strength 0.21
  24. Min Li · 1 shared paper, 2026 · strength 0.21
  25. Bo Wang · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.